Abstract
The metabolic and immunologic effects of short and long-term theophylline administration in recent onset Type I diabetic patients were studied in association with 'theophylline sensitivity' of lymphocytes in vitro as a marker of suppressive functions. Eighteen recent onset Type I diabetic patients entered the trial. Five were treated with theophylline (800 mg/d) for 1 mo (group A), 5 were treated with the theophylline (800 mg/d) for 8 mo (group B) and 8 were treated with placebo tablets (group C) in double blind. All patients were followed-up for 16-32 mo. A relationship between sensitivity to theophylline evaluated as inhibition of lymphocyte blastogenic response to Con A and the achievement of remission was observed. At the beginning of the study 8 patients were theophylline sensitive (Th+) (5 of group A, 2 of group B and 1 of group C) and 7 patients were theophylline resistant (Th-) (2 of group B and 5 of group C). Among the 9 Th+ patients, 6 reached the remission phase, while of the 7 Th- patients only 2 reached the remission phase. A high percentage (7/10) of the theophylline-treated patients achieved remission (4 of group A and 3 of group B), while only 3 of the 8 placebo treated patients achieved remission. In vivo theophylline effects were not improved by the longer (8 mo) treatment period. These results show that Th sensitivity in vitro can be considered a precocious marker of the clinical response to immunomodulating drugs in Type I diabetic patients. The favourable effects of theophylline treatment might provide the possibility of an immunomodulating drug free of side effects for recent onset Type I diabetes.
| Original language | English |
|---|---|
| Pages (from-to) | 113-118 |
| Number of pages | 6 |
| Journal | Diabetes, Nutrition and Metabolism - Clinical and Experimental |
| Volume | 1 |
| Issue number | 2 |
| Publication status | Published - 1988 |
Fingerprint
ASJC Scopus subject areas
- Food Science
Cite this
In vivo and in vitro effects of theophylline administration in recent onset, Type I, diabetic patients. / Secchi, A.; Crosti, F.; Pastore, M. R.; Pavoni, D.; Falqui, L.; Navone, P.; Pontiroli, A. E.; Ciboddo, G. F.; Rugarli, C.; Pozza, G.
In: Diabetes, Nutrition and Metabolism - Clinical and Experimental, Vol. 1, No. 2, 1988, p. 113-118.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - In vivo and in vitro effects of theophylline administration in recent onset, Type I, diabetic patients
AU - Secchi, A.
AU - Crosti, F.
AU - Pastore, M. R.
AU - Pavoni, D.
AU - Falqui, L.
AU - Navone, P.
AU - Pontiroli, A. E.
AU - Ciboddo, G. F.
AU - Rugarli, C.
AU - Pozza, G.
PY - 1988
Y1 - 1988
N2 - The metabolic and immunologic effects of short and long-term theophylline administration in recent onset Type I diabetic patients were studied in association with 'theophylline sensitivity' of lymphocytes in vitro as a marker of suppressive functions. Eighteen recent onset Type I diabetic patients entered the trial. Five were treated with theophylline (800 mg/d) for 1 mo (group A), 5 were treated with the theophylline (800 mg/d) for 8 mo (group B) and 8 were treated with placebo tablets (group C) in double blind. All patients were followed-up for 16-32 mo. A relationship between sensitivity to theophylline evaluated as inhibition of lymphocyte blastogenic response to Con A and the achievement of remission was observed. At the beginning of the study 8 patients were theophylline sensitive (Th+) (5 of group A, 2 of group B and 1 of group C) and 7 patients were theophylline resistant (Th-) (2 of group B and 5 of group C). Among the 9 Th+ patients, 6 reached the remission phase, while of the 7 Th- patients only 2 reached the remission phase. A high percentage (7/10) of the theophylline-treated patients achieved remission (4 of group A and 3 of group B), while only 3 of the 8 placebo treated patients achieved remission. In vivo theophylline effects were not improved by the longer (8 mo) treatment period. These results show that Th sensitivity in vitro can be considered a precocious marker of the clinical response to immunomodulating drugs in Type I diabetic patients. The favourable effects of theophylline treatment might provide the possibility of an immunomodulating drug free of side effects for recent onset Type I diabetes.
AB - The metabolic and immunologic effects of short and long-term theophylline administration in recent onset Type I diabetic patients were studied in association with 'theophylline sensitivity' of lymphocytes in vitro as a marker of suppressive functions. Eighteen recent onset Type I diabetic patients entered the trial. Five were treated with theophylline (800 mg/d) for 1 mo (group A), 5 were treated with the theophylline (800 mg/d) for 8 mo (group B) and 8 were treated with placebo tablets (group C) in double blind. All patients were followed-up for 16-32 mo. A relationship between sensitivity to theophylline evaluated as inhibition of lymphocyte blastogenic response to Con A and the achievement of remission was observed. At the beginning of the study 8 patients were theophylline sensitive (Th+) (5 of group A, 2 of group B and 1 of group C) and 7 patients were theophylline resistant (Th-) (2 of group B and 5 of group C). Among the 9 Th+ patients, 6 reached the remission phase, while of the 7 Th- patients only 2 reached the remission phase. A high percentage (7/10) of the theophylline-treated patients achieved remission (4 of group A and 3 of group B), while only 3 of the 8 placebo treated patients achieved remission. In vivo theophylline effects were not improved by the longer (8 mo) treatment period. These results show that Th sensitivity in vitro can be considered a precocious marker of the clinical response to immunomodulating drugs in Type I diabetic patients. The favourable effects of theophylline treatment might provide the possibility of an immunomodulating drug free of side effects for recent onset Type I diabetes.
UR - http://www.scopus.com/inward/record.url?scp=0024270053&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024270053&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0024270053
VL - 1
SP - 113
EP - 118
JO - Diabetes, Nutrition and Metabolism - Clinical and Experimental
JF - Diabetes, Nutrition and Metabolism - Clinical and Experimental
SN - 0394-3402
IS - 2
ER -